Education
About Us
Working with TipRanks
Follow Us
PharmaCyte Biotech (PMCB)
NASDAQ:PMCB
Total Valuation
PharmaCyte Biotech has a market cap or net worth of $8.50M. The enterprise value is $0.00.
Market Cap$8.50M
Enterprise Value$0.00
Share Statistics
PharmaCyte Biotech has 10,134,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,134,160
Owned by Insiders8.59%
Owned by Institutions1.22%
Financial Efficiency
PharmaCyte Biotech’s return on equity (ROE) is 0.59 and return on invested capital (ROIC) is -8.38%.
Return on Equity (ROE)0.59
Return on Assets (ROA)0.56
Return on Invested Capital (ROIC)-8.38%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee0.00
Profits Per Employee15.33M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PharmaCyte Biotech is ―. PharmaCyte Biotech’s PEG ratio is -0.00107.
PE Ratio―
PS Ratio0.00
PB Ratio0.18
Price to Fair Value0.18
Price to FCF-3.05
Price to Operating Cash Flow-1.24
PEG Ratio-0.00107
Income Statement
In the last 12 months, PharmaCyte Biotech had revenue of 0.00 and earned 30.66M in profits. Earnings per share was 3.19.
Revenue0.00
Gross Profit0.00
Operating Income-4.38M
Pretax Income30.66M
Net Income30.66M
EBITDA30.66M
Earnings Per Share (EPS)3.19
Cash Flow
In the last 12 months, operating cash flow was -4.52M and capital expenditures 0.00, giving a free cash flow of -4.52M billion.
Operating Cash Flow-4.52M
Free Cash Flow-4.52M
Free Cash Flow per Share-0.45
Dividends & Yields
PharmaCyte Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-51.88%
50-Day Moving Average0.90
200-Day Moving Average1.06
Relative Strength Index (RSI)44.86
Average Volume (3m)1.97M
Important Dates
PharmaCyte Biotech upcoming earnings date is Mar 16, 2022, Before Open (Confirmed).
Last Earnings DateDec 15, 2021
Next Earnings DateMar 16, 2022
Ex-Dividend Date―
Financial Position
PharmaCyte Biotech as a current ratio of 7.68, with Debt / Equity ratio of 0.00%
Current Ratio7.68
Quick Ratio7.68
Debt to Market Cap0.00
Net Debt to EBITDA-0.49
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PharmaCyte Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
PharmaCyte Biotech EV to EBITDA ratio is -0.20, with an EV/FCF ratio of 2.04.
EV to Sales0.00
EV to EBITDA-0.20
EV to Free Cash Flow2.04
EV to Operating Cash Flow2.04
Balance Sheet
PharmaCyte Biotech has $15.61M in cash and marketable securities with $0.00 in debt, giving a net cash position of $15.61M billion.
Cash & Marketable Securities$15.61M
Total Debt$0.00
Net Cash$15.61M
Net Cash Per Share$1.54
Tangible Book Value Per Share$6.87
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PharmaCyte Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―